|Articles|April 2, 2009

Cost-Effectiveness and Outcome Optimization Strategies in the Treatment of Residual Cardiovascular R
Volume 15
Issue 3

Cost-Effectiveness and Outcome Optimization Strategies in the Treatment of Residual Cardiovascular Risk Beyond LDL Cholesterol in the Managed Care Setting

Download PDF: Cost-Effectiveness and Outcome Optimization Strategies in the Treatment of Residual Cardiovascular Risk Beyond LDL Cholesterol in the Managed Care Setting

Articles in this issue

over 17 years ago

Article

Beyond LDL Cholesterol: The Role of Elevated Triglycerides and Low HDL Cholesterol in Residual CVD Risk Remaining After Statin Therapy

over 17 years ago

Article

Introduction

over 17 years ago

Article

Participating Faculty

over 17 years ago

Article

The Impact of Residual CVD Risk in the Managed Care Setting

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Cost-Effectiveness and Outcome Optimization Strategies in the Treatment of Residual Cardiovascular Risk Beyond LDL Cholesterol in the Managed Care Setting

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

Medicaid MFN Pricing Could Save $8.6 Billion

CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks

Cardiology Prices Vary Widely by Insurer and State

Active US Drug Shortages Rise for Third Straight Quarter

Early-Onset CKD Mortality Declines Globally as Incidence Continues to Rise